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Abstract 
Review on CEBPA, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: C/EBPa, CEBP 




Human C/EBPα is an intronless gene located on the 
minus strand of chromosome 19q. 
Transcription 
The C/EBPa mRNA (RNA messenger) consists of a 
short 5' unstranslated region (5'-UTR), a unique 
protein coding sequence (CDS) and a long 3'-UTR 
(Hendricks-Taylor et al., 1992). 
Protein 
Description 
Human C/EBPα mRNA gives rise to two protein 
products by using two different translation starting 
sites (Figure 1 and 2) (Calkhoven et al., 2000). 
Compared to full-length C/EBPA protein, P42, the 
shorter P30 isoform lacks N-terminal 117 amino 
acids (Lin et al., 1993). 
As a transcription factor, C/EBPA protein consists 
of DNA-binding domain (DBD) in its carboxyl-
terminal (C-terminal), which is conserved between 
C/ebp family members (Leutz et al., 2011).  
The highly conserved C-terminus includes the basic 
DNA binding leucine zipper domain (bZip).  
The bZip domain in turn consists of a basic region 
that represents the DNA binding domain (DBD), 
the fork domain and the leucine zipper domain 
(LZ).  
The bZip domain is indispensable for 
homodimerization and heterodimerization with 
other members of the C/EBP family. 
 
Figure 1: Human C/EBPa mRNA. 
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Figure 2: C/EBPa protein domains and interactions. 
 
This region is also involved in the interaction with 
other transcription factors (e.g. E2F, PU.1, c-JUN, 
RUNX1 and ETS1) (McNagny et al., 1998; 
Yamaguchi et al., 1999; Ramji and Foka, 2002; 
Nerlov, 2004; Koschmieder et al., 2005; Leutz et 
al., 2011). 
The N-terminus of C/EBPa consists of three 
transactivation domains (TA), which can interact 
with components of the transcriptional machinery 
(e.g. CBP/P300, TBP/TFIIB) (Nerlov and Ziff, 
1995; Kovacs et al., 2003; Schwartz et al., 2003), 
cell cycle regulators (e.g. E2F, CDK2, CDK4) 
(Porse et al., 2001; Porse et al., 2006) and 
chromatin remodellers (e.g. SWI/SNF) (Pedersen et 
al., 2001). 
Expression 
C/EBPa is mainly expressed in terminally 
differentiated cells, such as mature adipocytes and 
myelomonocytic cells. C/EBPa is also found 
expressed in skin, intestine, lung, adrenal gland, 
mammary gland, ovary, prostate, placenta (Oh and 
Smart, 1998; Birkenmeier et al., 1989). 
Localisation 
C/EBPa protein is localized in nucleus. 
Function 
C/EBPa homozygous null mice lack white adipose 
tissues (Wang et al., 1995), as well as mature 
granulocytes and granulocyte-macrophage 
precursors (Zhang et al., 1997; Heath et al., 2004). 
In addition, forced expression of C/EBPa can direct 
uncommitted progenitors to differentiate into 
adipocytes and granulocytes (Freytag et al., 1994; 
Radomska et al., 1998; Nerlov et al., 1998). Further 
studies suggest that C/EBPa plays important roles 
in lineage determination by activating lineage-
specific genes (Nerlov, 2004; Graf and Enver, 
2009). 
In hematopoiesis, C/EBPa is one of the key factors 
driving myeloid cell differentiation from 
hematopoietic stem cells by interacting with other 
proteins, such as the ETS family transcription factor 
PU.1, the ATP dependent chromatin remodeling 
complex SWI/SNF, the DNA modifying enzyme 
TET2 (McNagny et al., 1998; Koschmieder et al., 
2005; Leutz et al., 2011; Kallin et al., 2012). 
Ectopic expression of C/EBPa leads to cell cycle 
arrest via direct interaction with the key cell cycle 
regulators CDK2/4 and E2F (Porse et al., 2001; 
Porse et al., 2006). The N-terminal truncated form 
of C/EBPa, P30, has been shown to act as a 
dominant negative regulator of the full-length form, 
P42. Modulation of P30 expression level in mice 
can alter normal adipogenesis and granulopoiesis 
(Kirstetter et al., 2008). 
Notably, ectopic expression of C/EBPa in B and T-
lymphocyte precursors results in 
transdifferentiation into functional macrophages 
(Xie et al., 2004; Laiosa et al., 2006; Bussmann et 
al., 2009; Di Tullio et al., 2011; Kallin et al., 2012). 
Interestingly, C/EBPa mediated conversion of B 
lymphoma cells into macrophages impairs 
significantly its tumorigenicity, providing a novel 
strategy for lymphoma treatment (Rapino et al., 
2013). Moreover, a recent study showed that 
transient C/EBPa expression is also capable of 
facilitating the conversion of B cells into induced 
pluripotent stem cells (iPS cells) (Di Stefano et al., 
2014). 
Moreover, C/EBPa has been shown involved in 
lung development and airway epithelial 
differentiation (Cassel et al., 2000a; Cassel et al., 
2000b; Cassel et al., 2002). The conditional 
deletion of C/EBPa gene in respiratory epithelium 
results in respiratory arrest and death soon after 
birth. This phenotype is associated with 
proliferation of immature type II alveolar cells, 
which causes epithelial expansion and loss of air 
space (Martis et al., 2006; Basseres et al., 2006). 
Homology 
C/EBPa belongs to the CCAAT/enhancer binging 
protein family and is highly conserved across 
vertebrate species. Sequence alignments show that 
C/EBP members share several conserved regions 
including the bZip and transactivation domains 
(Leutz et al., 2011). 
Mutations 
Note 
Mutations of the C/EBPα gene have been detected 
in 7%-15% of Acute Myeloid Leukemia (AML) 
(Pabst et al., 2001b; Preudhomme et al., 2002; 
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Barjesteh van Waalwijk van Doorn-Khosrovani et 
al., 2003; Snaddon et al., 2003; Frohling et al., 
2004; Lin et al., 2005), around 4% of 
Myelodysplastic Syndrome (MDS) and Chronic 
Myeloid Leukemia (CML) (Shih et al., 2005). In 
addition, two familial cases of AML harboring 
C/EBPA mutations have been reported (Smith et 
al., 2004; Renneville et al., 2009). 
Germinal 
Germ line mutations of C/EBPα have been 
described for two familial cases of AML. In one 
Inherited acute myeloid leukemia case, a 
heterozygous deletion of cytosine 212 has been 
reported (Smith et al., 2004). Recently, the second 
family contained a heterozygous insertion of 
cytosine at nucleotide 217 (Renneville et al., 2009). 
These mutations result in frameshifts, leading to a 
premature termination of full-length C/EBPa P42 
isoform translation.  
Nonetheless, the alternative C/EBPa P30 isoform 
translation could be potentially privileged. P30 
isoform has dominant-negative activity on the full-
length P42 isoform. 
Somatic 
It has been shown that 7%-15% of AML harbor 
somatic mutations of the C/EBPα gene (Pabst et al., 
2001b; Preudhomme et al., 2002; Barjesteh van 
Waalwijk van Doorn-Khosrovani et al., 2003; 
Snaddon et al., 2003; Frohling et al., 2004; Lin et 
al., 2005). In addition, C/EBPα mutations have 
been detected in MDS and CML patient samples. 
These mutations can be basically divided into two 
categories: C-terminal in-frame ins/del mutations 
altering C/EBPA DNA-binding activities, and N-
terminal out-of-frame ins/del mutations impairing 
translation of full-length P42 isoform and leading 
aberrant expression of P30 isoform, which has 
dominant-negative activity on P42 isoform. The 
majority of leukemias with biallelic C/EBPA 
mutations harbor one allele with C-terminal 
mutations and the other one with N-terminal 
mutations. Tumors with homozygous N'-terminal or 
C'-terminal mutations are relatively rare. 
Implicated in 
Acute myeloid leukemia (AML) 
Disease 
Mutations in C/EBPα have been identified in 7-
15% of AML cases (Pabst et al., 2001b; 
Preudhomme et al., 2002; Barjesteh van Waalwijk 
van Doorn-Khosrovani et al., 2003; Snaddon et al., 
2003; Frohling et al., 2004; Lin et al., 2005). A 
meta-analysis of a cohort of 1175 patients reported 
that C/EBPα mutations are preferentially identified 
in M1, M2 and M4 FAB subtypes and associated 
with normal karyotype (Leroy et al., 2005). 
Prognosis 
It has been shown that AML patients harboring 
C/EBPα mutations have favorable prognosis 
(Preudhomme et al., 2002). 
Abnormal protein 
C-terminal in-frame ins/del mutations can alter 
C/EBPa DNA-binding activities, and N-terminal 
out-of-frame ins/del mutations impairing translation 
of full-length P42 isoform and leading to aberrant 
expression of P30 isoform, which has dominant-
negative activity on P42 isoform (Leroy et al., 
2005). 
Oncogenesis 
Mouse models harboring biallelic (C-terminal and 
N-terminal) C/EBPα mutations suggested that the 
co-existence of these mutations can increase the 
proliferation of long-term hematopoietic stem cells 
(LT-HSC) and override normal HSC homeostasis, 
leading to expansion of premalignant HSC 
(Kirstetter et al., 2008; Bereshchenko et al., 2009). 
Moreover, the fusion oncoproteins AML1-ETO 
(t(8;21)), CBFb-HYH11 (inv(16)) and PML-RARa 
(t(15;17)) suppress C/EBPA mRNA expression 
and/or protein activity in AML (Pabst et al., 2001a; 
Truong et al., 2003; Cilloni et al., 2003). 





It has been reported that C/EBPa is involved in 
several cases of BCP-ALL, although the prevalence 
of C/EBPa involved translocation need to be 
determined using larger cohorts (Chapiro et al., 
2006; Akasaka et al., 2007; Jeffries et al., 2014). In 
these BCP-ALL cases, C/EBPa is aberrantly 
expressed by juxtaposition to the immunoglobulin 
gene enhancer upon its rearrangement with the 
immunoglobulin heavy-chain locus. 
Oncogenesis 
Aberrant expression of C/EBPa in BCP-ALL 
samples harboring t(14;19)(q32;q13) suggests that 
C/EBPa may have oncogenic function in this 
disease, which is in contrast to its onco-suppressor 
role in AML (Chapiro et al., 2006). Further 
biological studies need to be performed to clarify 
this hypothesis. 
Non-small-cell lung cancer 
Disease 
The chromosomal region including C/EBPa was 
reported deleted in 50% stage II and IIIA lung 
adenocarcinomas (Girard et al., 2000). However, 
mutations of C/EBPa in lung cancer are rare. It has 
been as well reported that an upstream promoter 
region of the C/EBPa gene is hypermethylated in 
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approximately 65% of primary lung tumors (Tada 
et al., 2006). These evidences suggest that C/EBPa 
is a tumor suppressor in non-small-cell lung cancer. 
Oncogenesis 
Ectopic expression of C/EBPa in lung cancer cell 
lines results in significant growth arrest (Halmos et 
al., 2002; Costa et al., 2007). A transcriptional 
analysis identified that differentiation associated 
gene FoxA2 is a direct target gene of C/EBPa in 
lung cancer cell line (Halmos et al., 2004). 
Recently, using urethane-induced lung cancer 
model, it has been shown that C/EBPa expression is 
extinguished through p38alpha MAP kinase 
inactivation, leading to tumor progression (Sato et 
al., 2013), confirming a tumor suppressor role of 
C/EBPa in lung cancer. 
Skin squamous cell carcinoma 
Disease 
Although C/EBPa expression has been found in 
human precancerous skin lesions (Actinic 
Keratoses) and normal epidermis, its expression is 
undetectable in invasive squamous cell carcinoma 
samples (Thompson et al., 2011), suggesting a 
possible role as a tumor-suppressor in skin cancer. 
Oncogenesis 
In normal epidermis, C/EBPa expression is located 
in basal and suprabasal keratinocytes (Maytin and 
Habener, 1998; Thompson et al., 2011). Forced 
C/EBPa expression in a skin cancer cell line 
inhibits cell proliferation (Shim et al., 2005). 
Moreover, C/EBPa-null mice are highly susceptible 
to 7,12-dimethylbenz[a]anthracene- and UVB-
induced skin tumor development (Loomis et al., 
2007; Thompson et al., 2011). Notably, It has been 
shown that down-regulation of C/EBPa in skin 
cancer cells is associated with oncogenic Ras 
activation (Shim et al., 2005; Loomis et al., 2007). 
Prostate cancer 
Disease 
It has been shown that C/EBPa expression is down-
regulated in prostate cancer sample comparing to 
normal prostate tissue (Yin et al., 2006). 
Interestingly, one study showed that C/EBPa 
expression is sequestered in cytosol, which could 
impair its transcription factor activity (Zhang et al., 
2008). Although further studies need to be 
performed with larger prostate cancer cohorts for 
confirmation, these observations suggest an 
emerging tumor suppressor role of C/EBPa in 
prostate cancer. 
Oncogenesis 
C/EBPa is mainly expressed in basal layer in 
normal prostate. In most prostate adenocarcinoma 
samples, its expression level is low (Yin et al., 
2006; Zhang et al., 2008). Forced expression of 
C/EBPa in prostate cancer cell lines can inhibit 
PSA (Prostate Specific Antigen) expression and 
regulate negatively androgen receptor (AR) 
signaling (Chattopadhyay et al., 2006; Yin et al., 
2006; Zhang et al., 2010).  
In addition, in AR-negative prostate cancer cell 
lines, ectopically expressed C/EBPA protein can 
physically interact with Ku proteins (Ku70, Ku80) 
and Poly [ADP-ribose] polymerase 1 (PARP-1), 
conferring prostate cancer cells an increased 




The expression of C/EBPa is reduced in 
hepatocellular carcinoma samples and higher 
expression of C/EBPa in hepatocellular carcinoma 
reversibly correlated with the tumor size and 
clinical stage (Tomizawa et al., 2003). 
Oncogenesis 
Forced C/EBPa expression in hepatoma cell lines 
impairs proliferation and tumorigenicity (Watkins 
et al., 1996). Liver specific C/EBPa knock-in mice 
are resistant, at least partially, to 
diethylnitrosamine-induced hepatocellular 
carcinoma formation. These observations suggest a 
tumor suppressor role of C/EBPa in hepatocellular 
carcinoma (Tan et al., 2005). 
Head and neck squamous cell cancer 
Disease 
It has been reported that C/EBPa expression is 
down-regulated in squamous cell cancers in head 
and neck region. This down-regulation correlates 
with the degree of C/EBPa promoter methylation 
(Bennett et al., 2007). 
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